LRCX — Lam Research Corporation

The market is constructive following the July 29, 2026 earnings report: revenue of $6.72B and EPS of $1.81 beat expectations, gross margins expanded to 51.7%, and management signaled confidence via a 27% dividend increase and a $3B+ R&D lab investment. Wall Street consensus is Buy with a $370.41 average price target, and the forward narrative around AI/HBM-driven wafer-fab equipment demand remains strong.

Revenue has accelerated from $3.48B in Sep-2023 to $6.72B in Jun-2026. The last four reported quarters show YoY revenue growth of roughly +27.7%, +22.1%, +23.8%, and +30.0%; operating margin has expanded from ~29% in early FY24 to 37.4% in Q4 FY26. This is not a one-quarter blip — it is an accelerating up-cycle driven by AI, advanced packaging, HBM, and leading-edge logic. The main caution is cash conversion: Q4 FY26 operating cash flow of $1.46B ran below net income of $2.28B, and TTM OCF is slightly below the prior-year TTM, so earnings are growing faster than cash is landing in the bank.

Expensive on trailing metrics but closer to fair on forward numbers. Trailing P/E is 55.0x, price-to-sales is 17.1x versus a 5-year average of 9.4x, and price-to-book is 32.1x. However, the forward P/E on next-FY consensus EPS of $9.48 is about 33.6x, which is only slightly above LRCX's 5-year average P/E of 32.6x. The forward PEG is roughly 0.53, while the trailing PEG is 1.43. In short, the stock is not cheap, but it is not priced for perfection if FY27 estimates hold.

At $318.58, the market is pricing in the visible recovery rather than a speculative future: 33.6x forward EPS against a 32.6x historical average. If LRCX beats FY27 estimates and earns north of $10, the current price quickly becomes reasonable. If WFE orders wobble or export restrictions tighten, the de-rating could be sharp given the stock's 1.87 beta. This is a 'pay up for quality but respect the cycle' setup more than a 'priced-for-armageddon' or 'priced-for-paradise' one.

As of 2026-08-27, RSI is 50.41, squarely neutral. Price is 1.09% above the 20-day SMA, 4.23% below the 50-day SMA, and 24.12% above the 200-day SMA. The stock is in a consolidation/range-bound digestion phase after a massive 52-week range of $94.11–$438.50. The technical setup favors waiting for either a reclaim of the 50-day or a pullback toward the 200-day rather than chasing the immediate move.

• AI/HBM memory capex cycle: strong etch and deposition demand from AI accelerators and high-bandwidth memory stacks.
• US-China export controls on semiconductor equipment remain a structural overhang and can shift geographic revenue mix.
• Higher interest rates pressure long-duration, high-beta tech valuations; LRCX beta is 1.87.
• Semiconductor capex is inherently cyclical; memory customers can quickly cut or delay wafer-fab equipment orders.
• Government/CHIPS-type subsidies and local-content requirements continue to shape global fab construction and equipment demand.

• Q1 FY27 earnings expected late October 2026 — guidance will test whether the 30% revenue growth trajectory continues.
• CFO presentations at the Citi Global TMT Conference and Goldman Sachs Communicopia Conference in September 2026 could provide order/booking color.
• Dividend ex-date on September 23, 2026 for the newly raised $0.33 quarterly dividend.
• Continued AI/HBM buildout and advanced-packaging capacity additions, which directly benefit Lam's etch and deposition franchises.

• Escalating US-China export restrictions, which could remove a meaningful portion of the addressable WFE market.
• Cyclical downturn or memory oversupply causing customers to push out fab equipment orders.
• Customer concentration among a small number of leading-edge logic and memory fabs.
• Rich valuation leaves limited margin for error if FY27 estimates need to be revised downward.

Lam Research is a top-tier semi-cap franchise with real operating momentum, expanding margins, and direct exposure to the AI/HBM buildout. The balanced risk-reward at $318.58 — fair-forward multiple, rich trailing multiple, and a neutral technical picture — argues for patience: it is a solid long-term compounder, but not a clear bargain today. My lean is neutral, with a preference to add on weakness rather than chase strength.

Calculated by applying a 36.0x forward P/E — a modest ~10% premium to LRCX's 5-year average P/E of 32.6x, justified by accelerating AI/HBM demand, strong margin expansion, and 25–30% revenue growth — to next-FY consensus EPS of $9.48, yielding roughly $341.32.